Following these promising results in humanized mice, the first phase 1 human clinical trial with ZFN-CCR5 mutated CD4+ T cells was conducted, showing that these genetically modified CD4+ T cells were more resistant to HIV-1 infection and led to decrease viral loads during ART interruption (198). This evidence concerns the gene CD4 and HIV-1 infection.